onc201
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
2024 | Journal of Clinical Oncology
Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com
Publications
onc201
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
2023 | Cancer Discovery
onc201
Role of ClpP in the Anti-cancer Effects of Imipridone ONC201 and ONC206
American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023
onc201
ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023 –Orlando, FL
preclinical
The nucleoside analog antiviral CMX521 inhibits SARS-CoV-2 in human airway epithelial cell cultures and exhibits prophylactic and therapeutic efficacy against respiratory disease in a mouse model of SARS-CoV-2 infection
ICAR March 23, 2022
onc201
Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients
2021 SNO Annual Meeting Abstract CTNI-36
onc201
Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients
2021 SNO Annual Conference
onc206
IND-enabling characterization of dual DRD2-and ClpP-targeting agent ONC206 as the next imipridone for clinical neuro-oncology
Neuro-Oncology 2020
onc206
Predictive biomarker evaluation and molecular differentiation for imipridones ONC201 and ONC206
AACR annual meeting 2021, Abstract Number: 393
imipridones
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Neoplasia 2020 PMID: 33142238
